Will. I am rather more optimistic as I suspect we are further along the pain curve. We have one more capital raising to endure. This will take us to completion of phase 2 - if successful to that point we will be an attractive candidate either for acquisition or investment - ie. no more passing the hat around.
Also, we haven't given up with the EMA - we did get close in that one and the FDA trials will fill in some of the gaps with them. Downside for shareholders is more waiting - mid 2017 is my guess
TIS Price at posting:
4.3¢ Sentiment: Hold Disclosure: Held
